Certara, Inc. (CERT)

Insider Trading Filed: 2026-05-15

Key Insights

Director Cynthia Collins acquired 15,757 shares of common stock on May 14, 2026, through the vesting of restricted stock units granted on May 21, 2025, representing a routine equity compensation event with no cash outlay.
Collins now beneficially owns 51,846 shares of CERT stock directly following this transaction, indicating meaningful personal investment alignment with shareholder interests as a board member.
The RSU vesting occurred on the date of the company's annual meeting, which is a standard practice for equity grants and suggests no insider trading concerns or unusual timing patterns.
This is a non-discretionary equity compensation event rather than open market buying or selling, providing limited insight into management's current market sentiment or confidence in the stock valuation.

Insider Trading Filed: 2026-05-15

Key Insights

CFO John V.W. Reynders received 15,757 RSUs that vested on May 14, 2026 (the annual meeting date), converting to common stock at no cost, increasing his direct holdings to 26,466 shares—indicating routine equity compensation vesting.
Reynders was granted an additional 33,222 RSUs on the same date (May 14, 2026) that will vest in one year or at the next annual meeting, suggesting continued confidence in his CFO role and standard executive retention practices.
The total equity grant of approximately 49,000 RSUs represents significant compensation to the CFO but appears to be standard annual equity awards rather than extraordinary grants, with no evidence of insider selling that would suggest loss of confidence.

Insider Trading Filed: 2026-05-15

Key Insights

Eran Broshy, Chairman and Director of Certara, received 15,757 RSUs that vested on May 14, 2026 (the annual meeting date), converting them to common stock with zero acquisition cost, indicating standard equity compensation tied to annual vesting cycles.
Broshy was granted an additional 33,222 RSUs on May 14, 2026, representing a substantial new equity award that vests over one year or at the next annual meeting, demonstrating continued confidence in leadership and long-term incentive alignment.
Following the reported transactions, Broshy's direct beneficial ownership increased to 50,708 shares of common stock, reflecting cumulative equity stake building through regular compensation practices.
The use of RSUs as compensation and the pattern of vesting tied to annual meetings is typical for executive leadership, with no indication of discretionary buying or selling activity that might signal insider confidence shifts.

Insider Trading Filed: 2026-05-15

Key Insights

Director Arjun Bedi received 5,547 RSUs that vested on May 14, 2026 (the annual meeting date), converting to common stock with no monetary consideration, indicating routine equity compensation vesting.
Bedi was granted an additional 33,222 RSUs on May 14, 2026, vesting over one year or at the next annual meeting, representing a significant equity grant that aligns leadership incentives with shareholder value creation.
Total equity compensation of 38,769 shares granted/vested on the same day reflects standard director compensation practices at the annual meeting, with no indication of insider selling or loss of confidence in the company.

Insider Trading Filed: 2026-05-15

Key Insights

Chairman James Cashman III received 15,757 RSUs that vested on May 14, 2026, converting to common stock at $0 exercise price, indicating standard equity compensation rather than a market-based purchase.
An additional 33,222 RSUs were granted on May 14, 2026, vesting on the earlier of one-year anniversary or next annual meeting, showing continued equity incentive allocation for the company's leadership.
Total beneficial ownership after transactions is 484,197 shares held directly, representing meaningful insider stake by the Chairman in the company.
All RSU grants occurred at $0 price per the 2020 Incentive Plan, consistent with typical restricted stock compensation practices rather than open market trading activity.

Insider Trading Filed: 2026-05-15

Key Insights

Nancy Killefer, a Director at Certara, acquired 15,757 shares through vesting of RSUs granted on May 21, 2025, indicating she received equity compensation tied to company performance over the past year.
Killefer received an additional grant of 33,222 RSUs on May 14, 2026 (the annual meeting date), demonstrating continued equity incentive alignment with the company and shareholders going forward.
The director now beneficially owns 51,846 shares directly, showing meaningful personal investment in Certara's success, though this represents routine equity compensation rather than discretionary insider buying.
Both equity transactions occurred at $0 price, confirming these are compensation-related RSU vesting events rather than open-market purchases, which is typical for director stock awards.

Insider Trading Filed: 2026-05-15

Key Insights

Director Rosemary A. Crane acquired 15,757 shares through RSU vesting on May 14, 2026, with zero purchase price, indicating this was a scheduled equity compensation event rather than discretionary insider buying.
The transaction occurred on the company's annual meeting date (May 14, 2026), which is typical for RSU vesting schedules tied to corporate governance events.
Crane's total beneficial ownership increased to 45,672 shares following the vesting, representing a modest equity stake that suggests limited personal financial commitment beyond compensation packages.

Insider Trading Filed: 2026-05-15

Key Insights

Director Matthew M. Walsh acquired 15,757 shares through RSU vesting on May 14, 2026 (the annual meeting date), indicating routine equity compensation rather than discretionary insider buying.
Walsh received an additional grant of 33,222 RSUs on the same date with a one-year vesting schedule, showing continued confidence in the company's future with significant compensation tied to long-term value creation.
Total beneficial ownership increased to 213,316 shares following the vesting event, representing a material stake that aligns the director's interests with shareholders.
All transactions occurred at $0 price, confirming these are equity compensation events rather than open-market transactions, which reduces the signal regarding management's view of stock valuation.

Current Report Filed: 2026-05-15

Key Insights

Director election results show strong shareholder support for Arjun Bedi and Jon Resnick with over 99% approval, while Stephen McLean received notably lower support at 81.4% approval, suggesting potential governance or performance concerns with this director.
RSM US LLP was overwhelmingly ratified as the independent auditor with 99.5% approval and zero broker non-votes, indicating strong confidence in the company's financial reporting and audit processes.
Executive compensation was approved with 98.1% shareholder support, demonstrating investor confidence in management's pay practices and overall leadership performance despite Stephen McLean's lower director approval rating.
Broker non-votes of approximately 19.9 million shares on director elections suggest institutional investors may be abstaining or facing voting restrictions, representing roughly 7.6% of total votes cast on that proposal.

Insider Trading Filed: 2026-05-13

Key Insights

Daniel Corcoran, SVP and General Counsel, received a total of 234,805 equity awards on May 11, 2026, consisting of RSUs (74,074 shares) and PSUs (159,931 shares), representing significant long-term compensation alignment with company performance.
The PSU grants include two separate tranches with different performance periods (through March 31, 2028 and 2029) tied to total shareholder return thresholds with potential payout ranges from 0-200%, indicating management confidence in future company performance.
No insider selling activity is reported in this filing, only equity grants, which suggests executives are focused on accumulating shares rather than divesting—a generally positive indicator of confidence in company direction.
The RSU vesting schedule spans three years (2027-2029) with equal annual installments, demonstrating a structured retention strategy for a senior executive in a critical legal and compliance role.

Insider Trading Filed: 2026-05-13

Key Insights

Robert Aspbury, President of Predictive Technologies at Certara, received significant equity compensation totaling 531,309 shares in performance and restricted stock units, indicating strong executive retention focus by the company.
The grant includes 68,348 amended PSUs from the 2025 plan (with 0-200% payout based on TSR through March 2028) plus 129,629 new PSUs from the 2026 plan (similar structure through March 2029), showing the company's emphasis on long-term performance alignment.
RSU grants of 333,332 shares vest equally over three years (April 2027-2029), providing significant downside protection and multi-year equity exposure that typically indicates management confidence in company trajectory.
All securities were acquired at $0 exercise price with direct ownership, representing pure equity grants rather than market purchases, which is standard executive compensation but reflects no insider buying signal at current market valuations.

Insider Trading Filed: 2026-05-13

Key Insights

Leif E. Pedersen, President and Chief Commercial Officer, received significant equity compensation grants totaling 253,533 derivative securities (PSUs and RSUs) on May 11, 2026, indicating strong confidence from the board in his continued leadership and performance.
The grants include performance stock units with 0-200% payout multipliers based on total shareholder return targets through March 2028 and March 2029, aligning executive compensation with shareholder value creation rather than pure stock price appreciation.
RSU grants vest over three years (April 2027-2029) while PSUs have multi-year performance periods, demonstrating the company's focus on long-term retention and incentive alignment for senior management.
This is a routine equity compensation event for an executive officer with no insider selling activity reported, which is neutral to slightly positive as it shows stability in senior leadership without wealth diversification concerns.

Insider Trading Filed: 2026-05-13

Key Insights

Chief Human Resources Officer Rona Anhalt received substantial equity compensation totaling 198,258 shares worth of equity instruments (43,938 PSUs from prior year, 43,938 PSUs, 61,728 RSUs, and 92,592 PSUs), indicating significant executive retention focus by the company.
The majority of compensation is performance-based (136,530 PSUs vs. 61,728 RSUs), with payouts ranging from 0-200% based on total shareholder return thresholds through 2028-2029, aligning executive interests with long-term shareholder value creation.
No shares were sold or disposed of in this transaction, suggesting confidence in company prospects from a senior HR executive, though this is a grant rather than discretionary insider buying.
The RSU vesting schedule extends through April 2029 with equal annual installments, demonstrating multi-year retention incentives typical for executive compensation packages.

Insider Trading Filed: 2026-05-13

Key Insights

CEO Jon Matthew Resnick received a substantial equity grant of approximately 2.24 million shares worth in RSUs and PSUs on 05/11/2026, representing significant long-term incentive compensation tied to company performance.
The grant structure includes performance-based units (PSUs) with 0-200% payout potential based on stock price thresholds through 2028-2029, indicating management confidence in future stock appreciation and alignment with shareholder interests.
Resnick sold 24,377 shares at $6.31 to satisfy tax withholding obligations on RSU vesting, a routine compliance transaction that demonstrates one-third of the May 2026 RSU tranche vested immediately upon grant.
The executive retains direct ownership of 35,389 common shares after the tax withholding sale, with substantial future vesting scheduled through 2029, reflecting meaningful personal stake in company success.

Insider Trading Filed: 2026-05-13

Key Insights

CFO John Gallagher received 426,595 total equity awards on May 11, 2026, consisting of RSUs (129,629 shares vesting over 3 years) and PSUs (297,966 shares with 0-200% payout based on TSR performance through 2028-2029), indicating strong confidence in long-term company performance.
The significant grant of performance-based equity (70% of total awards) with substantial upside potential (up to 200% of target) suggests the compensation committee expects meaningful shareholder value creation and aligns executive incentives with stock performance.
Disposition of 102,522 PSUs from the prior year (granted May 2025) on the same day as new grants indicates possible vesting and settlement, though this is routine executive compensation management rather than a discretionary insider sale signal.

Quarterly Report Filed: 2026-05-11

Key Insights

The filing shows Q1 2026 operational data as of March 31, 2026, with comparison periods to Q1 2025, indicating Certara is tracking year-over-year performance in its software and services business.
The XBRL structured data reveals detailed debt facility disclosures including revolving credit facilities with SOFR-based variable rate components and term loan arrangements as of October 16, 2025, suggesting active debt management and refinancing activities.
Interest rate swap hedging instruments are documented across multiple periods (designated as cash flow hedges), indicating the company is actively managing interest rate exposure on its debt obligations.
The filing structure covers equity components (common stock, additional paid-in capital, retained earnings, accumulated other comprehensive income, and treasury stock) across multiple reporting periods, reflecting standard shareholder equity tracking.
Contingent liabilities are tracked with specific notation during the Q1 2026 period, suggesting potential material obligations that warrant investor attention regarding future financial impacts.

Current Report Filed: 2026-05-11

Key Insights

Certara completed the divestiture of its medical writing and regulatory services business to Veristat for $85 million in cash on May 8, 2026, representing a strategic shift toward core competencies and potential cash generation for debt reduction or reinvestment.
The transaction structure includes $15 million in escrow (subject to post-closing covenants) and up to $35 million in contingent earn-out payments based on business performance, indicating seller confidence but also retention of downside risk exposure.
The sale proceeds provide immediate liquidity that could improve Certara's financial position, though the divestiture reduces revenue-generating assets and suggests management prioritization of margin expansion or return of capital over growth in that segment.

Current Report Filed: 2026-04-22

Key Insights

Certara is divesting its global medical writing and regulatory services business to Veristat for $100 million upfront cash plus up to $35 million in contingent earn-out payments, representing a strategic portfolio optimization to focus on core operations.
The transaction structure includes $15 million held in escrow pending satisfaction of closing conditions, providing some downside protection while the earn-out component ties future value realization to post-closing business performance over a specified period.
The deal is subject to customary closing conditions including material adverse effect clauses and completion of internal reorganization steps, with transition services to be provided post-closing, indicating an orderly separation process.

Insider Trading Filed: 2026-04-03

Key Insights

The reporting person, Adrian McKemey, who is the President of Drug Development Solutions at Certara, Inc., exercised 10,849 restricted stock units (RSUs) on April 1, 2026, acquiring an equal number of common shares.
McKemey also sold 2,642 shares to cover tax withholding obligations, leaving him with a direct ownership of 8,207 shares.
The remaining two-thirds of the RSUs will vest and settle in equal parts on April 1, 2027 and April 1, 2028, indicating a continued long-term equity incentive alignment with the company.

Insider Trading Filed: 2026-04-03

Key Insights

The reporting person, Daniel Corcoran, exercised 10,849 restricted stock units (RSUs) and sold 5,751 shares to cover tax withholding obligations, indicating potential insider activity and portfolio rebalancing.
The remaining 21,698 RSUs will continue vesting in equal parts over the next two years, suggesting the reporting person maintains a long-term stake in the company.
The transaction price of $5.70 per share is close to the current market price, indicating the sale was likely for tax purposes rather than a bearish signal.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information